Zhang Wei-Han, Chen Xin-Zu, Yang Kun, Liu Kai, Chen Zhi-Xin, Zhang Bo, Zhou Zong-Guang, Hu Jian-Kun
Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.
Laboratory of Gastric Cancer, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.
World J Surg Oncol. 2015 Dec 8;13:332. doi: 10.1186/s12957-015-0744-x.
The aim of this study is to evaluate the safety and efficacy of bursectomy of D2 gastrectomy in terms of postoperative complications and short-term survival outcomes.
From January 2012 to December 2013, data of 406 gastric cancer patients with advanced tumor stages and who underwent D2 radical gastrectomy and were grouped according to whether bursectomy was performed or not in West China Hospital, Sichuan University, were analyzed.
Finally, 159 patients were in bursectomy group and 247 patients in non-bursectomy group. Surgical duration was 260.1 ± 43.4 min in the bursectomy group, compared to 227.9 ± 48.6 min in the non-bursectomy group (p < 0.001). The intraoperative blood loss was comparable between the bursectomy group and the non-bursectomy group (198.9 ± 63.5 vs. 201.1 ± 53.7 ml, p = 0.729). Postoperative morbidity rate showed no significant difference between the two groups, which were 23.3 % in the bursectomy group and 17.8 % in the non-bursectomy group, p = 0.179. The overall survival outcomes of patients were compared between the two groups of all patients (p = 0.055): patients who underwent distal gastrectomy (p = 0.129) and total gastrectomy (p = 0.016) and pT2-3 stage patients (p = 0.117) and pT4a stage patients (p = 0.128). The multivariate survival analysis identified that bursectomy or not, pT stage and pN stage were independent prognostic risk factors for the overall survival.
The bursectomy might increase the surgical duration when the D2 gastrectomy was done. Experienced surgeons can perform it safely. However, for the survival benefits of bursectomy, long-term, large sample sized, and high-quality randomized controlled trials are expected.
本研究旨在从术后并发症和短期生存结局方面评估D2胃切除术时进行脾切除术的安全性和有效性。
分析2012年1月至2013年12月在四川大学华西医院接受D2根治性胃切除术且肿瘤分期较晚的406例胃癌患者的数据,根据是否进行脾切除术进行分组。
最终,脾切除组159例患者,非脾切除组247例患者。脾切除组手术时间为260.1±43.4分钟,非脾切除组为227.9±48.6分钟(p<0.001)。脾切除组与非脾切除组术中出血量相当(198.9±63.5 vs. 201.1±53.7 ml,p=0.729)。两组术后发病率无显著差异,脾切除组为23.3%,非脾切除组为17.8%,p=0.179。比较了两组所有患者的总体生存结局(p=0.055):接受远端胃切除术的患者(p=0.129)、全胃切除术的患者(p=0.016)、pT2-3期患者(p=0.117)和pT4a期患者(p=0.128)。多因素生存分析确定,是否进行脾切除术、pT分期和pN分期是总体生存的独立预后危险因素。
进行D2胃切除术时,脾切除术可能会延长手术时间。经验丰富的外科医生可以安全地进行该手术。然而,关于脾切除术对生存的益处,期待长期、大样本量和高质量的随机对照试验。